221 related articles for article (PubMed ID: 36257585)
21. Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation.
Hsu FM; Cheng JC; Chang YL; Lee JM; Koong AC; Chuang EY
Sci Rep; 2015 May; 5():10291. PubMed ID: 25980316
[TBL] [Abstract][Full Text] [Related]
22. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
[TBL] [Abstract][Full Text] [Related]
23. Immunological Responses Associated With Neoadjuvant Therapy in the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma.
Takehara Y; Tamaki T; Mimura K; Saito K; Neupane P; Tada T; Watanabe Y; Hayase S; Saze Z; Yoshimoto Y; Sato H; Kono K; Suzuki Y
Anticancer Res; 2023 Oct; 43(10):4691-4700. PubMed ID: 37772585
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
26. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of a seven-lncRNA signature in patients with esophageal squamous cell carcinoma: a lncRNA expression analysis.
Weng NQ; Chi J; Wen J; Mai SJ; Zhang MY; Huang L; Liu J; Yang XZ; Xu GL; Fu JH; Wang HY
J Transl Med; 2020 Jan; 18(1):47. PubMed ID: 32005248
[TBL] [Abstract][Full Text] [Related]
28. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
[TBL] [Abstract][Full Text] [Related]
30. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
[TBL] [Abstract][Full Text] [Related]
31. Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma.
Liu J; Zhou WY; Luo XJ; Chen YX; Wong CW; Liu ZX; Bo Zheng J; Yu Mo H; Chen JQ; Li JJ; Zhong M; Xu YH; Zhang QH; Pu HY; Wu QN; Jin Y; Wang ZX; Xu RH; Luo HY
Clin Transl Med; 2023 Sep; 13(9):e1410. PubMed ID: 37712124
[TBL] [Abstract][Full Text] [Related]
32. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma.
Wen J; Fang S; Hu Y; Xi M; Weng Z; Pan C; Luo K; Ling Y; Lai R; Xie X; Lin X; Lin T; Chen J; Liu Q; Fu J; Yang H
EBioMedicine; 2022 Dec; 86():104371. PubMed ID: 36434949
[TBL] [Abstract][Full Text] [Related]
33. Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration.
Liu W; Yang HS; Zheng SY; Luo HH; Feng YF; Lei YY
BMC Bioinformatics; 2022 Sep; 23(1):406. PubMed ID: 36180848
[TBL] [Abstract][Full Text] [Related]
34. Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma.
Tong YS; Zhou XL; Wang XW; Wu QQ; Yang TX; Lv J; Yang JS; Zhu B; Cao XF
J Transl Med; 2014 Aug; 12():233. PubMed ID: 25169763
[TBL] [Abstract][Full Text] [Related]
35. Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma.
Wang P; Chen Y; Zheng Y; Fu Y; Ding Z
Dis Markers; 2021; 2021():5340240. PubMed ID: 34712369
[TBL] [Abstract][Full Text] [Related]
36. A more novel and robust gene signature predicts outcome in patients with esophageal squamous cell carcinoma.
Ma C; Luo H
Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102033. PubMed ID: 36265781
[TBL] [Abstract][Full Text] [Related]
37. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.
Tsutsumi S; Saeki H; Nakashima Y; Ito S; Oki E; Morita M; Oda Y; Okano S; Maehara Y
Cancer Sci; 2017 Jun; 108(6):1119-1127. PubMed ID: 28294486
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
[TBL] [Abstract][Full Text] [Related]
39. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
40. Protein-coding genes combined with long non-coding RNAs predict prognosis in esophageal squamous cell carcinoma patients as a novel clinical multi-dimensional signature.
Guo JC; Li CQ; Wang QY; Zhao JM; Ding JY; Li EM; Xu LY
Mol Biosyst; 2016 Oct; 12(11):3467-3477. PubMed ID: 27714034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]